相关实验视频
Updated: Jul 24, 2025

08:53
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
Published on: August 31, 2016
15.3K
血管造血干细胞移植的机构病例与死亡率之间的关联
Leerang Lim1, Eun Jin Jang2, Jun Woo Jo3
1Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Transplantation proceedings
|July 7, 2023
概括
血液造血干细胞移植 (HSCT) 的机构病例数量较高与更好的患者存活率有关. 这项研究发现,对于异构和自身的HSCT手术,在高体积中心的死亡率较低.
科学领域:
- 医学研究 医学研究
- 移植科学 移植科学
- 医疗服务研究 医疗服务研究
背景情况:
- 造血干细胞移植 (HSCT) 是一项具有高风险的复杂程序.
- 之前的研究表明,更高的机构病例数量可以改善复杂程序的结果.
- HSCT体积与患者死亡率之间的关系需要进一步研究.
研究的目的:
- 分析每年机构HSCT病例数量与患者死亡率之间的关联.
- 为了确定更高的病例数量是否与HSCT后更好的生存率相关.
主要方法:
- 利用国家医疗保险服务数据库进行数据提取.
- 分析了46个韩国中心的16213个HSCT程序 (2007-2018).
- 根据平均年度病例负载,分类中心为低 (≤25例/年) 和高体积. 采用多变量逻辑回归来估计1年死亡率的调整几率比率.
主要成果:
- 低体积中心的1年死亡率显著高于异性HSCT (调整的OR 1.17).
- 在低体积中心 (调整的OR1.03) 观察到自主HSCT的1年死亡率没有显著差异.
- 长期死亡率在低体积的中心显着更糟糕,无论是异构的 (调整HR 1.17) 和自身的HSCT (调整HR 1.09).
结论:
- 更高的机构HSCT病例数量与短期和长期生存率的改善有关.
- 这表明HSCT患者的结果可能依赖于体积.
- 将高体积中心的HSCT程序集中在高体积中心可能会提高整体生存率.
相关概念视频
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Bone Marrow Sampling and Transplants
363
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
363
Hematopoiesis
5.4K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.4K
Multipotency of Hematopoietic Stem Cells
3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K
Tissue Transplantation
415
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
415

